Literature DB >> 30137553

Evaluating the Clinical Relevance of Psychotic Experiences in Low- and Middle-Income Countries.

Jordan E DeVylder1, Ai Koyanagi2,3.   

Abstract

Mesh：

Year:  2018        PMID： 30137553      PMCID： PMC6192499          DOI： 10.1093/schbul/sby120

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN： 0586-7614            Impact factor:   9.306


× No keyword cloud information.
  13 in total

1.  Stress Sensitivity and Psychotic Experiences in 39 Low- and Middle-Income Countries.

Authors:  Jordan E DeVylder; Ai Koyanagi; Jay Unick; Hans Oh; Boyoung Nam; Andrew Stickley
Journal:  Schizophr Bull       Date:  2016-04-24       Impact factor: 9.306

2.  The continuum of psychotic symptoms in the general population: a cross-national study.

Authors:  Roberto Nuevo; Somnath Chatterji; Emese Verdes; Nirmala Naidoo; Celso Arango; José Luis Ayuso-Mateos
Journal:  Schizophr Bull       Date:  2010-09-13       Impact factor: 9.306

3.  Epidemiology of depression with psychotic experiences and its association with chronic physical conditions in 47 low- and middle-income countries.

Authors:  A Koyanagi; H Oh; B Stubbs; J M Haro; J E DeVylder
Journal:  Psychol Med       Date:  2016-10-27       Impact factor: 7.723

4.  The Association between Sleep Problems and Psychotic Symptoms in the General Population: A Global Perspective.

Authors:  Ai Koyanagi; Andrew Stickley
Journal:  Sleep       Date:  2015-12-01       Impact factor: 5.849

5.  Association Between Psychotic Experiences and Subsequent Suicidal Thoughts and Behaviors: A Cross-National Analysis From the World Health Organization World Mental Health Surveys.

Authors:  Evelyn J Bromet; Matthew K Nock; Sukanta Saha; Carmen C W Lim; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Jordi Alonso; Guilherme Borges; Ronny Bruffaerts; Louisa Degenhardt; Giovanni de Girolamo; Peter de Jonge; Silvia Florescu; Oye Gureje; Josep M Haro; Yanling He; Chiyi Hu; Elie G Karam; Viviane Kovess-Masfety; Sing Lee; Jean-Pierre Lepine; Zeina Mneimneh; Fernando Navarro-Mateu; Akin Ojagbemi; José Posada-Villa; Nancy A Sampson; Kate M Scott; Juan C Stagnaro; Maria C Viana; Miguel Xavier; Ronald C Kessler; John J McGrath
Journal:  JAMA Psychiatry       Date:  2017-11-01       Impact factor: 21.596

Review 6.  Income inequality and schizophrenia: increased schizophrenia incidence in countries with high levels of income inequality.

Authors:  Jonathan K Burns; Andrew Tomita; Amy S Kapadia
Journal:  Int J Soc Psychiatry       Date:  2013-04-16

Review 7.  Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016.

Authors:  Fiona J Charlson; Alize J Ferrari; Damian F Santomauro; Sandra Diminic; Emily Stockings; James G Scott; John J McGrath; Harvey A Whiteford
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

8.  The association between psychosis and severe pain in community-dwelling adults: Findings from 44 low- and middle-income countries.

Authors:  Ai Koyanagi; Andrew Stickley
Journal:  J Psychiatr Res       Date:  2015-07-18       Impact factor: 4.791

9.  "Excessive thinking" as explanatory model for schizophrenia: impacts on stigma and "moral" status in Mainland China.

Authors:  Lawrence H Yang; Michael R Phillips; Graciete Lo; Yuwen Chou; Xiaoli Zhang; Kim Hopper
Journal:  Schizophr Bull       Date:  2009-02-04       Impact factor: 9.306

10.  Psychotic Experiences and Related Distress: A Cross-national Comparison and Network Analysis Based on 7141 Participants From 13 Countries.

Authors:  Caroline Wüsten; Björn Schlier; Edo S Jaya; Eduardo Fonseca-Pedrero; Emmanuelle Peters; Hélène Verdoux; Todd S Woodward; Tim B Ziermans; Tania M Lincoln
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306
View more
  1 in total

1.  Changes in psychotic-like experiences and related influential factors in technical secondary school and college students during COVID-19.

Authors:  Meng Sun; Dongfang Wang; Ling Jing; Liang Zhou
Journal:  Schizophr Res       Date:  2021-03-13       Impact factor: 4.662
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.